Former President Donald Trump has proposed a phased tariff plan of up to 200% on imported generic drugs by 2028 to encourage US manufacturing. As the largest supplier of generics to the US, Indian pharma companies face significant long-term risks to their export revenue and profit margins. Investors should monitor how major exporters adapt their manufacturing strategy to this potential trade barrier.
Detailed Coverage
Former President Donald Trump has announced a new trade policy that proposes heavy tariffs on generic medications imported into the United States. The plan, scheduled to begin on August 1, 2026, features a two-year grace period with zero tariffs, followed by a 100% duty for one year, and finally a 200% tariff by 2028. This move is designed to shift generic drug production into the United States by making imports significantly more expensive.
Impact on India’s Pharmaceutical Exports
India is a major supplier of affordable medications to the US, accounting for approximately $9.7 billion in pharmaceutical exports during 2025. According to industry data, Indian firms supply nearly half of all generic prescriptions in the US. Large companies such as Sun Pharmaceutical Industries, Cipla, and Dr. Reddy’s Laboratories have built substantial market shares in the US by providing cost-effective alternatives to expensive branded drugs. For these companies, the US market is a primary driver of revenue, and any restriction on their ability to supply generics could create pressure on their overall profit margins and growth plans.
Strategic Challenges for Indian Manufacturers
The proposed policy specifically targets generic drugs while leaving patented and branded innovative medicines unaffected. This creates a focused risk for the Indian pharmaceutical sector, which is heavily reliant on the high-volume, low-cost generic model. To avoid these tariffs, companies would theoretically need to establish or expand manufacturing facilities within the US. However, setting up a new production site involves massive capital spending, longer timelines, and higher operational costs compared to India. Smaller or mid-sized Indian pharma companies may lack the cash flow or balance sheet flexibility to fund such a transition, potentially leading to a loss of market share.
Sector and Trade Context
This policy is part of a broader shift in US trade policy that may affect multiple sectors beyond pharmaceuticals. The potential for higher tariffs on imports from several countries adds a layer of uncertainty for Indian exporters who are already managing risks related to pricing pressure and regulatory compliance in the US market. While major Indian drugmakers have historically demonstrated the ability to adapt to changing regulatory environments, a 200% tariff is a significant hurdle that could change the economics of the entire generic business model.
Investors should track how these companies address the need for US-based manufacturing and whether they can offset rising costs through higher-value product portfolios. The final impact will depend on the actual implementation of these tariffs and whether bilateral trade negotiations between Washington and New Delhi provide any exemptions for the healthcare sector.